摘要:
The present invention relates to substituted phenyl-piperazine compounds of general formula (I), a process for their preparation, medicaments comprising said substituted phenyl-piperazine compounds as well as the use of said substituted phenyl-piperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.
摘要:
The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said nitro-substituted phenylpiperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.
摘要:
The present invention relates to the use of compounds of the general Formula (XIII): wherein A7 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; A8 is C(R14)2, O, S, or NR12; A9 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; m is 0, or 1 q is 0, or 1 r is 0, or 1 R12 is H, CH3, CH2—CH3, C6H5, OCH3, OCH2—CH3, OH, or SH; R13 is H, CH3, or CH2—CH3; R14 is H, alkyl, alkoxy, OH, or SH;
摘要翻译:本发明涉及通式(XIII)化合物的用途:其中A 7为C = O,C = S,SO 2,CH-OR 13,C = NR 12或CH 2 -CHOR 13; A8为C(R14)2,O,S或NR12; A9为C = O,C = S,SO2,CH-OR13,C = NR12或CH2-CHOR13; m为0或1 q为0或1 r为0,或1 R 12为H,CH 3,CH 2 -CH 3,C 6 H 5,OCH 3,OCH 2 -CH 3,OH或SH; R 13是H,CH 3或CH 2 -CH 3; R 14是H,烷基,烷氧基,OH或SH;
摘要:
The present invention relates to the use of compounds of the general Formula (I): wherein in Formula (I), R is H, alkyl, cycloalkyl, aryl or heteroaryl; R1 is H, alkyl, cycloalkyl, aryl or heteroaryl; R2 is H, alkyl, cycloalkyl, aryl or heteroaryl; A1 and A2 each independently represent an optionally substituted C1-C20-alkyl group which may contain one or more group(s) Z, or a monocyclic or polycyclic optionally substituted aromatic or non-aromatic ring system which may contain one or more group(s) X, and in case of a polycyclic ring system, said system contains at least one aromatic ring; Z is selected from the group consisting of S, O, N, NR4, CO, CO2, CS, SO or SO2 X is selected from the group consisting of S, O, N, NR4, SO or SO2.
摘要翻译:本发明涉及通式(I)的化合物的用途:其中在式(I)中,R为H,烷基,环烷基,芳基或杂芳基; R 1是H,烷基,环烷基,芳基或杂芳基; R 2是H,烷基,环烷基,芳基或杂芳基; A 1和A 2各自独立地表示任选取代的C 1 -C 20 -C 20 - 烷基,其可以含有 一个或多个Z基团或可以含有一个或多个基团X的单环或多环任选取代的芳族或非芳族环系统,并且在多环系统的情况下,所述体系包含至少一个 芳香环 Z选自S,O,N,NR 4,CO,CO 2,CS,SO或SO 2 X 选自S,O,N,NR 4,SO或SO 2。
摘要:
The present invention relates to the use of compounds of the general Formula (XIII): In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.
摘要:
The present invention relates to the use of compounds of the general Formula (XIII): wherein A7 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; A8 is C(R14)2, O, S, or NR12; A9 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; m is 0, or 1 q is 0, or 1 r is 0, or 1 R12 is H, CH3, CH2—CH3, C6H5, OCH3, OCH2—CH3, OH, or SH; R13 is H, CH3, or CH2—CH3; R14 is H, alkyl, alkoxy, OH, or SH;
摘要翻译:本发明涉及通式(XIII)化合物的用途:其中A 7为CO,CS,SO 2,CH-OR 13, C-NR 12或CH 2 -CHOR 13; A 8是C(R 14)2,O,S或NR 12; A 9是CO,CS,SO 2,CH -OR 13,C-NR 12或CH < 2> -CHOR 13< 13> m为0或1 q为0或1 r为0,或1 R 12为H,CH 3,CH 2 - CH 3,C 6 H 5,OCH 3,OCH 2,-CH 2,CH 3, 3,OH或SH; R 13是H,CH 3或CH 2 -CH 3; R 14是H,烷基,烷氧基,OH或SH;
摘要:
The present invention relates to compounds of the general formula (III) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof, wherein R3 is H, —C(O)NRaRb, halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR4′OR5′, NH2, amine, alkylamine, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl, or haloalkyloxy; R4 is H, halogen, alkyl, —C(NR7)NR7R8, —(CH2)paryl, —(CH2)pNR7R8, —C(O)NR7R8, —N═CR7R8, —NR7C(O)R8, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hyodroxyalkylamino, alkylamino, heteroaryl, or aryl; R5 is halogen, alkyl, —C(NR7)NR7R8, —(CH2)paryl, —(CH2)pNR7R8, —C(O)NR7R8, —N═CR7R8, —NR7C(O)R8, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl.
摘要翻译:本发明涉及通式(III)的化合物或其药学上可接受的盐与酸或碱,或其药学上可接受的前药或立体异构体,其中R 3是H,-C( 卤素,烷基,卤代烷基,芳基,杂芳基,OH,SH,NR 4'或O 5 NH 2,胺,烷基胺,烷氧基,环烷基,杂环烷基,羟基烷基或卤代烷氧基; R 4是H,卤素,烷基,-C(NR 7)NR 7 R 8, - ( CH 2芳基, - (CH 2 CH 2)n NR 7 R 12 8,-C(O)NR 7 R 8,-N-CR 7 R 8 C 0(O)R 8,环烷基,杂环烷基,卤代烷基,羟基烷基,羟基烷基氨基,烷基氨基,杂芳基或芳基; R 5是卤素,烷基,-C(NR 7)NR 7 R 8, - (CH 3) (CH 2)n,NR 2,R 2,R 2,R 3, > 8,-C(O)NR 7 R 8,-N-CR 7 R 8, (O)R 8,环烷基,杂环烷基,卤代烷基,羟基烷基,羟基烷基氨基,烷基氨基,杂芳基或芳基。
摘要:
The present invention relates to the use of compounds of the general Formula (I): wherein in Formula (I), R is H, alkyl, cycloalkyl, aryl or heteroaryl; R1 is H, alkyl, cycloalkyl, aryl or heteroaryl; R2 is H, alkyl, cycloalkyl, aryl or heteroaryl; A1 and A2 each independently represent an optionally substituted C1-C20-alkyl group which may contain one or more group(s) Z, or a monocyclic or polycyclic optionally substituted aromatic or non-aromatic ring system which may contain one or more group(s) X, and in case of a polycyclic ring system, said system contains at least one aromatic ring; Z is selected from the group consisting of S, O, N, NR4, CO, CO2, CS, SO or SO2 X is selected from the group consisting of S, O, N, NR4, SO or SO2;
摘要:
The present invention relates to compounds of the general formula (III) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof, wherein R3 is H, —C(O)NRaRb, halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR4′OR5′, NH2, amine, alkylamine, alkoxy, cycloalkyl, heterocycloalkyl, hydroxyalkyl, or haloalkyloxy; R4 is H, halogen, alkyl, —C(NR7)NR7R8, —(CH2)paryl, —(CH2)pNR7R8, —C(O)NR7R8, —N═CR7R8, —NR7C(O)R8, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hyodroxyalkylamino, alkylamino, heteroaryl, or aryl; R5 is halogen, alkyl, —C(NR7)NR7R8, —(CH2)paryl, —(CH2)pNR7R8, —C(O)NR7R8, —N═CR7R8, —NR7C(O)R8, cycloalkyl, heterocycloalkyl, haloalkyl, hydroxyalkyl, hydroxyalkylamino, alkylamino, heteroaryl, or aryl.
摘要翻译:本发明涉及通式(III)的化合物或其药学上可接受的盐与酸或碱或其药学上可接受的前药或立体异构体,其中R 3是H,-C(O)NR a R b,卤素,烷基, 卤代烷基,芳基,杂芳基,OH,SH,NR4'OR5',NH2,胺,烷基胺,烷氧基,环烷基,杂环烷基,羟基烷基或卤代烷氧基。 R 4是H,卤素,烷基,-C(NR 7)NR 7 R 8, - (CH 2)paryl, - (CH 2)p NR 17 R 8,-C(O)NR 7 R 8,-N-CR 7 R 8,-NR 7 C(O)R 8,环烷基,杂环烷基, 卤代烷基,羟基烷基,羟基烷基氨基,烷基氨基,杂芳基或芳基; R5是卤素,烷基,-C(NR7)NR7R8, - (CH2)paryl, - (CH2)pNR7R8,-C(O)NR7R8,-N-CR7R8,-NR7C(O)R8,环烷基,杂环烷基,卤代烷基, 羟基烷基,羟基烷基氨基,烷基氨基,杂芳基或芳基。